Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.

Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R (2006)
Eur J Health Econ 7(4): 290-296.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ;
Abstract
We carried out a cost-effectiveness evaluation of transdermal fentanyl compared to three other widely used opioids: transdermal buprenorphine, sustained-release morphine, and controlled-release oxycodone from a third-party-payers perspective. A decision analytic model with data from a structured database search and from panel data and assumptions was used to derive both cost and utility results. Probabilistic sensitivity analysis was performed to ensure the findings. Transdermal fentanyl patients gain more quality adjusted life-days or quality-adjusted life-years per euro. The incremental cost per quality-adjusted life-year is 1,625.65 euro for transdermal fentanyl compared to sustained-release morphine and 1,003.03 euro compared to CO, and it is cost-saving compared to transdermal buprenorphine (-203.38 euro per patient). Transdermal fentanyl is thus cost-effective compared to both sustained-release morphine and CO and dominant compared to transdermal buprenorphine in the treatment of adults with nonmalignant moderate to severe chronic pain.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006;7(4):290-296.
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., & Sabatowski, R. (2006). Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ, 7(4), 290-296.
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., and Sabatowski, R. (2006). Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ 7, 290-296.
Greiner, W., et al., 2006. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ, 7(4), p 290-296.
W. Greiner, et al., “Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.”, Eur J Health Econ, vol. 7, 2006, pp. 290-296.
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., Sabatowski, R.: Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 7, 290-296 (2006).
Greiner, Wolfgang, Lehmann, K, Earnshaw, S, Bug, C, and Sabatowski, R. “Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.”. Eur J Health Econ 7.4 (2006): 290-296.
This data publication is cited in the following publications:
This publication cites the following data publications:

9 Citations in Europe PMC

Data provided by Europe PubMed Central.

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M., Appl Health Econ Health Policy 11(3), 2013
PMID: 23616247
Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH., Clin Ther 35(5), 2013
PMID: 23587608
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.
Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M., Value Health 16(2), 2013
PMID: 23538186
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Wielage R, Bansal M, Wilson K, Klein R, Happich M., Spine 38(11), 2013
PMID: 23250234
Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
Hass B, Lungershausen J, Hertel N, Poulsen Nautrup B, Kotowa W, Liedgens H., Eur J Health Econ 10(3), 2009
PMID: 19101743
Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP., Clin Drug Investig 28(9), 2008
PMID: 18666805

37 References

Data provided by Europe PubMed Central.


AUTHOR UNKNOWN, 0
Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.
Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA., Palliat Med 14(2), 2000
PMID: 10829145
Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.
Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, Rutstein J, Lacouture PG., Arch. Intern. Med. 160(6), 2000
PMID: 10737286
Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?
Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD., J Pain Symptom Manage 18(4), 1999
PMID: 10534967
Utility assessments of opioid treatment for chronic pain.
Schmier JK, Palmer CS, Flood EM, Gourlay G., Pain Med 3(3), 2002
PMID: 15099257

AUTHOR UNKNOWN, 0
The impact of nausea and vomiting on women: a burden of early pregnancy.
Smith C, Crowther C, Beilby J, Dandeaux J., Aust N Z J Obstet Gynaecol 40(4), 2000
PMID: 11194422
Health-related quality of life and hand eczema--a comparison of two instruments, including factor analysis.
Wallenhammar LM, Nyfjall M, Lindberg M, Meding B., J. Invest. Dermatol. 122(6), 2004
PMID: 15175027

World, Cancer pain relief and palliative care(), 1990

AUTHOR UNKNOWN, 0

World, Cancer pain relief and palliative care(), 2004

Export

0 Marked Publications

Open Data PUB

Sources

PMID: 16983521
PubMed | Europe PMC

Search this title in

Google Scholar